Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Rivaroxaban versus Aspirin after Atrial Fibrillation Ablation – Cardiology Insights and Heart Health
AI Generated
Apr 15, 2026, 17:30

Rivaroxaban versus Aspirin after Atrial Fibrillation Ablation – Cardiology Insights and Heart Health

Cardiology Insights and Heart Health shared a post on LinkedIn about a recent article by Atul Verma et al, adding:

“Catheter ablation can eliminate atrial fibrillation (AF), but does it eliminate the associated stroke risk?

Current clinical guidelines advise indefinite anticoagulation after atrial fibrillation ablation based on a patient’s stroke risk score, regardless of the procedure’s success.

This recent international RCT aimed to assess if long-term oral anticoagulant therapy remains necessary in cases with successful catheter ablation, potentially eliminating this medication for some patients.

The study included 1284 patients with:

  • ≥1-year post-successful AF ablation
  • Moderate stroke risk (CHA2DS2-VASc score ≥1, or ≥2 for women and patients with vascular disease)
  • No recurrent atrial tachyarrhythmia

Patients were randomized to:

  • Control: 70-120 mg aspirin
  • Anticoagulant: 15 mg rivaroxaban

Composite primary outcome: stroke, systemic embolism, or new covert embolic stroke (≥15 mm infarct on MRI) at 3-year follow-up

  • 5 events (rivaroxaban) versus 9 events (aspirin)
  • RR 0.56 (95 percent CI 0.19-1.65), P=0.28

Secondary outcome: stroke/systemic embolism alone

  • RR = 0.72 (95 percent CI 0.23-2.25)

The 95 percent confidence intervals for the risk ratios of both the primary and secondary efficacy measures crossed 1, indicating no statistically significant benefit.

Safety outcomes:

  • No significant difference in fatal/major bleeding – HR 2.51 (95 percent CI 0.79-7.95)
  • Higher minor and clinically relevant nonmajor bleeding incidence with rivaroxaban

Researchers noted that the incidences of primary and secondary outcomes were much lower than anticipated, with previous studies involving patients of similar stroke risk having higher rates.

They attributed this to catheter ablation being effective at reducing stroke risk or to selection bias of participants chosen for the study.

Strengths:

  • Randomized and international design
  • 3-year follow-up
  • MRI detection of subclinical cerebral infarcts

Limitations:

  • Underpowered results due to unexpectedly low event rates
  • Predominantly older, male population
  • Limited applicability to patients with very high stroke risk

Future trials

  • Investigate higher stroke risk populations
  • Compare discontinuation to placebo rather than aspirin
  • Have greater power for clinical stroke outcomes
  • Incorporate continuous remote rhythm monitoring to better assess AF burden post-ablation

In patients with moderate stroke risk and a successful AF ablation, rivaroxaban did not significantly reduce stroke risk compared with aspirin, but did have higher non-major bleeding risk.

While these findings do not support routine discontinuation of anticoagulation with aspirin, they suggest that stroke risk after a successful ablation may be lower than previously assumed and prompt further investigation into individualized anticoagulation strategies.”

Title: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation

Authors: Atul Verma, David H. Birnie, Chenyang Jiang, Hein Heidbüchel, Gerhard Hindricks, Paulus Kirchhof, Jeff S. Healey, Yunhe Wang, Nikolaos Dagres, Marc W. Deyell, Prashanthan Sanders, Rajeev K. Pathak, Pieter Koopman, Dieter Nuyens, Paul Novak, Guy Amit, Charles Dussault, Bhavanesh Makanjee, Russell Quinn, Umjeet Jolly, Leon Iden, Malte Kuniss, Mukul Sharma, Andrew Ha, Vidal Essebag, Jean Champagne, Michael D. Hill, Eric E. Smith, George A. Wells

Rivaroxaban versus Aspirin after Atrial Fibrillation Ablation - Cardiology Insights and Heart Health

Stay updated on all scientific advances with Hemostasis Today.

Andrew Ha Aspirin Atrial Fibrillation Atul Verma Bhavanesh Makanjee Cardiology Insights and Heart Health Charles Dussault Chenyang Jiang David H. Birnie Dieter Nuyens Eric E. Smith George A. Wells Gerhard Hindricks Guy Amit Health Hein Heidbüchel Hematology Hemostasis News Hemostasis Today Jean Champagne Jeff S Healey Leon Iden Malte Kuniss Marc W. Deyell Medicine Michael D. Hill Mukul Sharma Nikolaos Dagres Paul Novak Paulus Kirchhof Pieter Koopman Prashanthan Sanders Rajeev K. Pathak Rivaroxaban Russell Quinn Umjeet Jolly Vidal Essebag Yunhe Wang
NewsFeed